In separate research introduced on the current SNMMI 2024 convention, the positron emission tomography (PET) radiotracer 18F-flotufolastat demonstrated no urinary retention in sufferers with major prostate most cancers (PCa) and facilitated a 15 p.c larger proportion of biochemical failure-free survival compared to standard imaging for guided salvage radiotherapy in sufferers with recurrent PCa.
In a single examine evaluating 18F-flotufolastat (Posluma, Blue Earth Diagnostics) and 68Ga-PSMA-11-PET in 124 sufferers with major PCa, researchers discovered that 18 p.c of major tumors positioned close to the bladder within the 68Ga-PSMA-11-PET group (3/17) had been obscured by radioactivity within the bladder compared no obscured tumors with 18F-flotufolastat (0/24). The examine authors additionally reported a 27.4 p.c charge of halo artifacts with the 68Ga-PSMA-11-PET cohort (17/62) in distinction to 4.8 p.c (3/62) for these within the 18F-flotufolastat group.1
The researchers additionally emphasised that there was no ureter retention with 18F-flotufolastat compared to 21 p.c (13/62) for males within the 68Ga-PSMA-11-PET group.1
David Gauden, D.Phil, mentioned these examine outcomes throughout an interview on the SNMMI convention.
“Their findings had been clinically impactful of their opinion in that they’d a a lot decrease background radioactivity within the bladder (with 18F-flotufolastat) after they had been evaluating the scans. (This) gave them extra confidence of their diagnostic findings after they evaluated it on a multi-point scale of background (radiopharmaceutical) exercise, main them to consider that once you’re on the lookout for native recurrences, utilizing an agent with this decrease bladder excretion could possibly be clinically helpful in serving to with the administration of those sufferers,” famous Gauden, the chief govt officer for Blue Earth Diagnostics.
(Editor’s observe: For associated content material, see “Examine: 18F-Flotufolastat PET Imaging Adjustments Therapy in 89 P.c of Sufferers with Prostate Most cancers Recurrence,” “May Pluvicto Have a Position in Taxane-Naïve mCRPC?: an Interview with Oliver Sartor, MD” and “SNMMI: PSMA-18F DCFPyL Adjustments Therapy for PCa Recurrence in Vital Variety of Sufferers with Low PSAs.”)
In a separate examine of 110 sufferers with biochemical recurrence of PCa after radical prostatectomy, researchers in contrast 18F-flotufolastat PET-guided salvage radiotherapy (SRT) to traditional SRT. Though the researchers conceded a scarcity of statistical significance, they discovered that the 18F-flotufolastat PET-guided group had 8 p.c, 15 p.c, and 21 p.c larger charges of biochemical failure-free survival at one, two and three years, respectively, than those that had standard SRT.2
“Though it was a small examine with no statistically important discovering, there have been developments towards longer biochemical progression-free survival for the group the place the radiotherapy was guided by PET imaging along with the usual area … ,” added Gauden.
For extra insights from Mr. Gauden, watch the video under.
References
1. Rauscher I, Langbein T, Fuetterer CS, Weber W, Eiber M. Analysis of qualitative and quantitative PET parameters in major prostate most cancers sufferers: double-match comparability of 18F-flotufolastat and 68Ga-PSMA-11-PET. Offered on the 2024 Society of Nuclear Medication and Molecular Imaging Annual Assembly, June 8-11, Toronto, Canada. Obtainable at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 10, 2024.
2. Rauscher I, Vogel MME, Gschwend J, Peeken JC, Eiber M. 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy in recurrent prostate most cancers. Offered on the 2024 Society of Nuclear Medication and Molecular Imaging Annual Assembly, June 8-11, Toronto, Canada. Obtainable at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm . Accessed June 10, 2024.
